The role of funding and policies on innovation in cancer drug development.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Clinical Cancer Research in South America and Potential Health Economic Impacts.Healthcare (Basel, Switzerland) · 2023
   Article
2. Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE.Clinics and practice · 2022
   Review
3. Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?Healthcare (Basel, Switzerland) · 2022
   Article
4. The political economics of cancer drug discovery and pricing.Drug discovery today · 2020
   Review
5. Modifying Adaptive Therapy to Enhance Competitive Suppression.Cancers · 2020
   Article
6. The recent landscape of cancer research worldwide: a bibliometric and network analysis.Oncotarget · 2018
   Article
7. Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?Social science & medicine (1982) · 2015
   Review
8. Philanthropic partnerships and the future of cancer research.Nature reviews. Cancer · 2015
   Review
9. Statistical research on the bioactivity of new marine natural products discovered during the 28 years from 1985 to 2012.Marine drugs · 2015
   Article
10. Gene function in schistosomes: recent advances toward a cure.Frontiers in genetics · 2015
    Article
11. Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care.The EPMA journal · 2013
    Article
12. Optimizing investigator-led oncology research in Europe.Haematologica · 2012
    Article
13. Emphasising the European Union's Commitment to Cancer Research: a helicopter view of the Seventh Framework Programme for Research and Technological Development.The oncologist · 2012
    Article
14. Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases - Is It Time to Update the EU's Orphan Regulation? And if so, What Should be Changed?Biomedicine hub
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.